NCT06397222View on ClinicalTrials.gov

Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
DRUG

Sin-Bev-SIRT

Sintilimab 200mg I.V. q3w and bevacizumab 7.5mg/kg I.V. q3w will be started at 3-7 days after the first SIRT. Treatment of sintilimab and bevacizumab will last up to 24 months. Patients will be allowed to have sintilimab or bevacizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.

Trial Locations (1)

510260

RECRUITING

the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

Second Affiliated Hospital of Guangzhou Medical University

OTHER